2-[[(2,3-dimethylphenoxy)acetyl]amino]-5,6-dihydro-4H-cyclopenta[b]thiophene-3-carboxamide |
an inhibitor identified due to its activity against genotype 4d |
Hepatitis C virus genotype 4a |
|
6-(2-ethoxyphenyl)-3-(2-methylfuran-3-yl)[1,2,4]triazolo[3,4-b][1,3,4]thiadiazole |
an inhibitor identified due to its activity against genotype 4d |
Hepatitis C virus genotype 4a |
|
additional information |
N-(3-cyano-5,6,7,8-tetrahydro-4H-cyclohepta[b]thiophen-2-yl)-2-phenoxyacetamide and N-(3-cyano-5,6,7,8-tetrahydro-4H-cyclohepta[b]thiophen-2-yl)-2-(naphthalen-2-yloxy)acetamide are not inhibitory. The inhibitory efficacy of four computer-designed and chemically-synthesized small-molecule compounds is evaluated against in vitro-expressed NS3/4A protease from HCV genotype 4a, the most prevalent genotype in Egypt, using a fluorescence-based enzymatic assay, overview. Molecular modeling. No inhibition by N-(3-cyano-5,6,7,8-tetrahydro-4H-cyclohepta[b]thiophen-2-yl)-2-phenoxyacetamide (BE115) and N-(3-cyano-5,6,7,8-tetrahydro-4H-cyclohepta[b]thiophen-2-yl)-2-(naphthalen-2-yloxy)acetamide (BR116) |
Hepatitis C virus genotype 4a |
|
N-(3-cyano-4,5,6,7-tetrahydrobenzo[b]thien-2-yl)-2-(naphthalen-2-yloxy)acetamide |
i.e. BE114 |
Hepatitis C virus genotype 4a |
|
N-(3-cyano-4,5,6,7-tetrahydrobenzo[b]thien-2-yl)-2-phenoxyacetamide |
i.e. BE113 |
Hepatitis C virus genotype 4a |
|